Clinical trials
Acute Kidney Disease clinical trials
Below are recruiting acute kidney disease clinical trials, each written for real people, not researchers. We’re tracking 317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06897605RecruitingPhase 2
Dapagliflozin for anemia in kidney disease
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
Al MansurahAges 18 years+ - NCT06935786Recruiting
Sedentary lifestyle and health risks in kidney disease
This study looks at how a sedentary (mostly sitting or lying down) lifestyle affects people with advanced chronic kidney disease. It aims to see if being less active is linked to higher risks of death or major health problems.
PoriAges 40 years+ - NCT06998862RecruitingPhase 3
Colchicine for people with chronic kidney disease
This trial tests whether colchicine, a drug that reduces inflammation, can help prevent further heart problems or strokes in people with moderate chronic kidney disease. You may be eligible if you have kidney disease and have had a heart attack, stroke, or related event in the past.
Madrid, MadridAges 18–99 - NCT07119372RecruitingPhase 3
New drug for anemia from kidney disease on dialysis
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
MinskAges 18–75 - NCT07182422RecruitingPhase 4
AST-120 for kidney protection after acute kidney injury
This trial tests if the drug AST-120 (Kremezin) can help protect your kidneys and slow down further kidney decline after a recent acute kidney injury. It is for people who had a moderate to severe kidney injury during a hospital stay and now have mild to moderate chronic kidney damage.
TaoyuanAges 18–80 - NCT07187713RecruitingPhase 4
Study of ACE Reno, Pico Cell Matrix for kidney health
This trial tests a new treatment called ACE Reno, Pico Cell Matrix to see if it can improve kidney function in people with chronic kidney disease (CKD) at various stages. It may be an option if you have early to moderate kidney issues (including after a transplant) and are already on standard therapies.
Giza, GZAges 18–80 - NCT07231939Recruiting
Testing diabetes drugs to protect kidneys after heart procedures
This study is testing whether a class of diabetes medicines called SGLT2 inhibitors (specifically empagliflozin or dapagliflozin) can prevent kidney injury after heart procedures that use contrast dye.
BydgoszczAges 18 years+ - NCT07338669Recruiting
Hamburg study on acute kidney injury in hospitalized adults
This study follows hospitalized adults with or without acute kidney injury to learn more about the condition. You may join if you are 18 or older and can give consent.
HamburgAges 18 years+ - NCT07209527Enrolling by invitationEarly Phase 1
Truway diagnostic tools in primary care
This trial tests new diagnostic tools that doctors can use in primary care. Researchers want to see if these tools help find the right diagnosis faster and more accurately.
New York, New YorkAges Any age - NCT06823115Enrolling by invitation
Worldwide study of kidney injury in newborns
This study looks at how common acute kidney injury is in newborns in the intensive care unit. It helps doctors understand which babies are at risk and how to prevent kidney problems.
Birmingham, AlabamaAges birth–2 weeks - NCT06463964Enrolling by invitation
Predicting kidney injury in emergency heart failure patients
This study looks at what factors might predict acute kidney injury (sudden kidney damage) in people who come to the emergency room with acute decompensated heart failure (a sudden worsening of heart failure). The goal is to help doctors identify who is at highest risk so they can take steps to protect the kidneys.
SohagAges 18 years+ - NCT05870007Enrolling by invitationPhase 2
Atorvastatin and alkalizing treatment for autosomal dominant PKD
This Phase 2 study tests whether atorvastatin plus an “alkalizing” treatment (sodium bicarbonate) can slow or improve disease effects in people with autosomal dominant polycystic kidney disease (ADPKD). It specifically targets metabolic acidosis (when the body becomes “too acidic”), which may worsen kidney health.
New Taipei CityAges 18 years+ - NCT05161078Enrolling by invitation
Studies CARPEDIEM care for newborns and babies in participating hospitals
This trial looks at how to improve outcomes for newborns and infants who receive CARPEDIEM as part of routine hospital care. It aims to see whether an interdisciplinary team approach can make treatment safer and more effective.
Palo Alto, CaliforniaAges Any age - NCT04343417Enrolling by invitation
Kidney biopsy study that stores samples for research
This study collects and stores kidney biopsy samples (and related information) to help researchers understand kidney diseases. You may be able to join if you are already scheduled for a kidney biopsy and can consent.
New Haven, ConnecticutAges 18–99 - NCT06937307RecruitingPhase 2
Droxidopa for low blood pressure in cirrhosis with kidney injury
This trial tests a medication called droxidopa to see if it can raise blood pressure in people with cirrhosis who also have acute kidney injury. If you have low blood pressure and are in the hospital with these conditions, this study may help improve your kidney function.
New York, New YorkAges 18–70 - NCT05071131Recruiting
Inulin supplement to improve gut health in kidney disease
This trial studies whether taking inulin—a dietary fiber—can improve gut bacteria and the gut barrier in people with end-stage kidney disease on hemodialysis. It may help reduce gut-related problems that can affect overall health in kidney disease.
BerlinAges 18–75 - NCT04397159Recruiting
Exercise program to reduce tiredness in some kidney patients
This trial studies whether doing a combination exercise program can reduce “fatigability,” meaning feeling unusually tired or weak during activity, in Veterans with moderate-to-advanced chronic kidney disease. It also compares results with people without kidney disease and checks for safety, especially for heart and joint health.
Washington D.C., District of ColumbiaAges 50–85 - NCT06329622RecruitingPhase 3
Does Ketosteril help muscle loss in kidney disease?
This study tests whether a medicine called Ketosteril can improve muscle strength and function in people with moderate to severe chronic kidney disease (CKD) who also have sarcopenia (age-related muscle loss).
ShanghaiAges Any age - NCT07729683Recruiting
Testing wakame seaweed for kidney disease patients
This study tests whether eating a daily dose of wakame seaweed can lower certain waste products (AGEs) in your blood that build up with kidney disease. It's for people with moderate chronic kidney disease who are already on standard protective medications.
La RochelleAges 18–90 - NCT06738394Recruiting
Exercise study for older adults with kidney disease
This study tests whether a supervised exercise program can help older adults with chronic kidney disease improve their physical function and stay active. You have to be able to do exercise and not be on dialysis.
Winston-Salem, North CarolinaAges 65–100 - NCT07419828RecruitingPhase 3
Study of HRS-1780 for chronic kidney disease
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
Nanjing, JiangsuAges 18–80 - NCT06229990RecruitingPhase 4
Using furosemide stress test to stop kidney replacement therapy
This study tests whether a furosemide (a water pill) stress test can help doctors decide when to safely stop continuous kidney replacement therapy in ICU patients with severe acute kidney injury. It may allow you to come off the machine sooner if your kidneys respond well.
Chiang MaiAges 20 years+ - NCT03054142Recruiting
Study tracking kidney injury using blood creatinine changes
This study looks at people with acute (sudden) kidney injury, based on changes in a blood test called creatinine. By tracking these patterns during hospitalization, it may help improve how acute kidney injury is identified and managed.
Guangzhou, GuangdongAges Any age - NCT03711617Recruiting
Study of waste products and outcomes in chronic kidney disease
This study looks at “uremic toxins,” which are waste products that build up when kidney function is reduced, and how they relate to health outcomes in people with chronic kidney disease. The results may help doctors better understand what to monitor and target to improve care.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Acute Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute kidney disease?
- Yes. Clin2 currently lists 317 recruiting acute kidney disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute kidney disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute kidney disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.